A Phase 2, Multicenter, Single Arm Study to Evaluate the Effect of PAD Followed by Autologous Stem-cell Transplantation(ASCT) on the Concentrations of Bone Metabolites in Patients With Newly Diagnosed Multiple Myeloma(MM)

Trial Profile

A Phase 2, Multicenter, Single Arm Study to Evaluate the Effect of PAD Followed by Autologous Stem-cell Transplantation(ASCT) on the Concentrations of Bone Metabolites in Patients With Newly Diagnosed Multiple Myeloma(MM)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Dexamethasone; Doxorubicin; Epidoxoform
  • Indications Multiple myeloma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jul 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 21 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top